RESUMO
Objective:To investigate the efficacy of pidotimod in the treatment of elderly patients with bronchial pneumonia and its effect on immune function. Methods: Totally 85 cases of elderly patients with bronchial pneumonia were randomly divided into two groups:the pidotimod treatment group (43 cases) and the conventional therapy group (42 cases). The conventional therapy group was given moxifloxacin 400 mg·d-1 , ivd, the pidotimod treatment group was additionally with pidotimod oral solutions 800 mg,po,bid, and the treatment course was 10 days. The changes of immune function in the two groups were detected, and the symptoms including fever, cough, asthma, rale and lung spots in X-ray radiation and the symptom duration in the two groups were also compared. Results:After the treatment, the levels of CD4, CD4 / CD8 and NK cells in the two groups were significantly higher than those before the treat-ment, the level of CD8 cells and IgA, IgG, IgM expression levels were significantly lower than those before the treatment (P<0. 05), and the changes in the pidotimod treatment group were much notable than those in the conventional therapy group(P<0. 05). The in-cidence of fever, cough, asthma, rale and lung spots in X-ray radiation in the pidotimod treatment group was lower than that in the con-ventional therapy group(P<0. 01), and the symptom duration was shorter than that in the conventional therapy group(P<0. 01). Conclusion:The mechanisms of pidotimod in the effective treatment of bronchial pneumonia in elderly patients are relative to the im-provement of T cell subsets, NK cells and humoral immunity levels and the enhancement of immunity.